To hear about similar clinical trials, please enter your email below
Trial Title:
Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care
NCT ID:
NCT06648733
Condition:
Cancer
Heart Failure
COPD
Conditions: Official terms:
Heart Failure
Conditions: Keywords:
Palliative Care
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Supportive Care
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
Structured pharmaceutical discharge management
Description:
These patients will receive structured pharmaceutical discharge management from inpatient
to outpatient care.
Arm group label:
Prospective patients
Summary:
The transition of palliative care patients from inpatient to outpatient care is aimed to
be improved through structured pharmaceutical discharge management by a trained
pharmacist. This data will be compared with retrospective cases.
Detailed description:
As part of a prospective observational study with a retrospective comparison group, a
pharmacist should, on request, check the discharge medication planned by the primary care
physicians before discharge and discuss it with the various colleagues providing
(follow-up) care. In addition, the availability in the outpatient "medicine cabinet" and
the possibility of prescribing by the responsible GPs (by telephone) should be checked in
advance. In addition, longitudinal focus groups with relevant stakeholders are to be
conducted to collect quantitative data as well as qualitative data on the views of those
providing and receiving treatment.
There will be cooperation with the Specialized Outpatient Palliative Care Service
Muenster to ensure sufficient case numbers and a low rate of missing values through
partial use of the standard care data from the "Information System Palliative Care"
(ISPC) program they use.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
All individual indications for general and specialised palliative care as part of routine
clinical practice (e.g.):
- advanced, malignant tumour disease
- advanced, chronic obstructive pulmonary disease
- Patients with advanced disease and limited life expectancy (approx. 12 months)
Further care in the SOPC Muenster (prospective data) Sufficient understanding of the
German language to be able to understand the information and consent form
Exclusion Criteria:
Impossibility of understanding the information and declaration of consent.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University Hospital Muenster
Address:
City:
Muenster
Zip:
48149
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Philipp Lenz, Prof. Dr. med.
Phone:
+49 (0)251 8353052
Email:
philipp.lenz@ukmuenster.de
Investigator:
Last name:
Christoph Klaas, Dr. rer. nat.
Email:
Principal Investigator
Investigator:
Last name:
Constanze Rémi, Dr. rer. biol. hum.
Email:
Sub-Investigator
Investigator:
Last name:
Janina Krüger, Dr. med.
Email:
Sub-Investigator
Investigator:
Last name:
Sofie May
Email:
Sub-Investigator
Investigator:
Last name:
Florian Bernhardt
Email:
Sub-Investigator
Start date:
June 20, 2024
Completion date:
December 31, 2025
Lead sponsor:
Agency:
University Hospital Muenster
Agency class:
Other
Collaborator:
Agency:
University Hospital Munich
Agency class:
Other
Source:
University Hospital Muenster
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06648733
